| Investor | Value | Of portfolio | Shares | Change | Quarter |
|---|---|---|---|---|---|
| Renaissance Technologies | $6.5M | 0.01% | 1.53M | +57% | Q2 2026 |
From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors
No member of Congress has disclosed a BCYC trade since 2025.
From House and Senate STOCK Act reports. Members disclose trades, not holdings, as value ranges up to 45 days later, so amounts are estimates and “last move” is a hint at who still holds it, not a position. All recent congress trades
| Date | Insider | Transaction | Shares | Value |
|---|---|---|---|---|
| Jan 1, 2026 | Baker Bros Advisors L.P.Beneficial Owner of more than 10% of a Class of Security | Stock Award(Grant) at price 0.00 per share. | 38K | — |
| Jan 1, 2026 | Hoppenot HerveDirector | Stock Award(Grant) at price 0.00 per share. | 3K | — |
| Oct 2, 2025 | Hannay Michael Charles FergusonOfficer | Sale at price 8.40 - 8.41 per share. | 723 | $6.08K |
| Oct 1, 2025 | Young Alethia R.Chief Financial Officer | Sale at price 8.40 - 8.60 per share. | 482 | $4.10K |
| Oct 1, 2025 | Swanton Robert CharlesDirector | Sale at price 8.55 per share. | 102 | $872 |
| Apr 2, 2025 | Lee KevinChief Executive Officer | Sale at price 7.48 - 8.02 per share. | 5.7K | $43.61K |
| Apr 2, 2025 | Milnes AlistairChief Operating Officer | Sale at price 7.48 - 8.02 per share. | 2.2K | $16.85K |
| Apr 2, 2025 | Hannay Michael Charles FergusonOfficer | Sale at price 7.48 - 8.02 per share. | 733 | $5.74K |
| Apr 1, 2025 | Young Alethia R.Chief Financial Officer | Sale at price 8.02 per share. | 215 | $1.72K |
| Jan 5, 2025 | Thompson Travis AlvinOfficer | Sale at price 14.09 - 15.00 per share. | 4.6K | $67.29K |
| Jan 2, 2025 | Skynner MichaelChief Technology Officer | Sale at price 14.09 - 14.75 per share. | 4.2K | $60.12K |
| Jan 2, 2025 | Lee KevinChief Executive Officer | Sale at price 14.09 - 14.75 per share. | 12.1K | $172.95K |
| Jan 2, 2025 | Crockett NigelOfficer | Sale at price 14.09 - 14.75 per share. | 3.5K | $50.20K |
| Jan 2, 2025 | Milnes AlistairChief Operating Officer | Sale at price 14.09 - 14.75 per share. | 5.5K | $78.31K |
| Jan 2, 2025 | Hannay Michael Charles FergusonOfficer | Sale at price 14.09 - 14.75 per share. | 2.1K | $30.00K |
| Jan 1, 2025 | Baker Bros Advisors L.P.Beneficial Owner of more than 10% of a Class of Security | Stock Award(Grant) at price 0.00 per share. | 8.8K | — |
| Jan 1, 2025 | Kender Richard NDirector | Stock Award(Grant) at price 0.00 per share. | 6.3K | — |
| Jan 1, 2025 | Legault PierreDirector | Stock Award(Grant) at price 0.00 per share. | 12.5K | — |
| Jan 1, 2025 | Gutierrez-Ramos Jose-CarlosDirector | Stock Award(Grant) at price 0.00 per share. | 6.3K | — |
| Jan 1, 2025 | Skynner MichaelChief Technology Officer | Stock Award(Grant) at price 0.00 per share. | 35K | — |
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Year |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -9.3 | -10.7 | -19.0 | 1.7 | -0.6 | -9.6 | -9.0 | 7.0 | -10.9 | -1.4 | −48.7% | ||
| 2025 | -4.4 | -18.1 | -22.6 | 0.8 | -4.0 | -15.5 | 22.6 | -13.4 | 4.9 | 4.3 | -7.3 | -5.3 | −49.4% |
| 2024 | -3.5 | 43.8 | -0.8 | -5.8 | -5.4 | -8.8 | 20.1 | -11.6 | 5.3 | 3.6 | -13.0 | -31.4 | −22.6% |
| 2023 | -6.7 | -17.7 | -6.4 | -7.1 | 21.4 | 6.4 | -3.6 | -11.6 | -7.6 | -25.1 | -4.3 | 25.6 | −38.9% |
| 2022 | -19.8 | -2.7 | -7.6 | -46.5 | -31.9 | 4.9 | 40.4 | 12.3 | -12.1 | 6.4 | 17.0 | 2.2 | −51.4% |
| 2021 | 49.4 | -5.7 | 18.2 | 3.8 | -4.8 | 2.9 | 4.1 | 13.0 | 16.5 | 23.6 | 4.6 | 13.2 | +239.1% |
| 2020 | 15.4 | 18.8 | 5.6 | -6.2 | 39.6 | -11.9 | 0.4 | 13.7 | 6.0 | -2.8 | 15.4 | -16.0 | +90.3% |
| 2019 | -13.9 | -17.9 | -11.1 | 55.2 | -15.2 | -9.3 | 7.6 | −19.3% |
Buy / hold / sell counts
Bicycle Therapeutics plc, a clinical-stage pharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. The company's products pipeline include zelenectide pevedotin, a bicycle toxin conjugate (BTC), which is in phase II clinical trials for the treatment of high nectin-4 expressing tumors; nuzefatide pevedotin (EphA2), a BTC that is in phase I/II clinical trials to treat Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle tumor-targeted immune cell agonist molecule, which is in phase I/II targeting nectin-4 and agonizing CD137; and BT1702, a theranostic BRC molecule targeting MT1-MMP for which IND-enabling activities are ongoing. In addition, it develops Novel CNS targets, which is in preclinical trial targeting CNS disease; Novel neuromuscular targets, which is in preclinical trial targeting neuromuscular disease; and programs that are in preclinical trial targeting radiopharmaceutical. Further, the company collaborates with biopharmaceutical companies and organizations to develop programs in therapeutic areas. It has collaboration and license agreement with Bayer Consumer Care AG; Novartis Pharma AG; Ionis Pharmaceuticals, Inc.; Genentech, Inc; and AstraZeneca AB. Bicycle Therapeutics plc was incorporated in 2009 and is headquartered in Cambridge, the United Kingdom.